JP2005510563A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005510563A5 JP2005510563A5 JP2003547370A JP2003547370A JP2005510563A5 JP 2005510563 A5 JP2005510563 A5 JP 2005510563A5 JP 2003547370 A JP2003547370 A JP 2003547370A JP 2003547370 A JP2003547370 A JP 2003547370A JP 2005510563 A5 JP2005510563 A5 JP 2005510563A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition
- pharmaceutically acceptable
- acceptable salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 82
- 239000000203 mixture Substances 0.000 claims 34
- 150000003839 salts Chemical class 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 10
- 239000000556 agonist Substances 0.000 claims 8
- 239000002830 appetite depressant Substances 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 239000003937 drug carrier Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 208000030814 Eating disease Diseases 0.000 claims 6
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 6
- 102000004877 Insulin Human genes 0.000 claims 6
- 108090001061 Insulin Proteins 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 235000014632 disordered eating Nutrition 0.000 claims 6
- 229940125396 insulin Drugs 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 239000000883 anti-obesity agent Substances 0.000 claims 4
- 229940125710 antiobesity agent Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 claims 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000004474 heteroalkylene group Chemical group 0.000 claims 3
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 2
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 claims 2
- SXKBTDJJEQQEGE-UHFFFAOYSA-N 3-(3,5-dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonic acid [4-(thiazol-2-ylsulfamoyl)-phenyl]-amide Chemical compound CCC=1OC2=CC(S(=O)(=O)NC=3C=CC(=CC=3)S(=O)(=O)NC=3SC=CN=3)=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 SXKBTDJJEQQEGE-UHFFFAOYSA-N 0.000 claims 2
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 claims 2
- 229940118148 Aldose reductase inhibitor Drugs 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims 2
- QTQMRBZOBKYXCG-MHZLTWQESA-N GW 1929 Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCN(C)C=1N=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 QTQMRBZOBKYXCG-MHZLTWQESA-N 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 102000000536 PPAR gamma Human genes 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 2
- 229940123659 Sorbitol dehydrogenase inhibitor Drugs 0.000 claims 2
- 229940100389 Sulfonylurea Drugs 0.000 claims 2
- 229960002632 acarbose Drugs 0.000 claims 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 2
- 239000003288 aldose reductase inhibitor Substances 0.000 claims 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 229960001761 chlorpropamide Drugs 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229960004580 glibenclamide Drugs 0.000 claims 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 2
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 2
- 229960003105 metformin Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 229960005095 pioglitazone Drugs 0.000 claims 2
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 229960001641 troglitazone Drugs 0.000 claims 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 2
- -1 (styrenyl) methyl Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 0 *Cc1cc(NC(CCC(CC2)(CCN2C2CCCC2)c(cc2)ccc2-c2cccc(C#N)c2)=O)ccc1 Chemical compound *Cc1cc(NC(CCC(CC2)(CCN2C2CCCC2)c(cc2)ccc2-c2cccc(C#N)c2)=O)ccc1 0.000 description 1
- GEIBEOSSYAMBAM-UHFFFAOYSA-N CN(CC(Nc(cc1)cc(C(F)(F)F)c1Cl)=O)C(CC1)(CCN1C1CCCC1)c(cc1)ccc1-c1cc(C#N)ccc1 Chemical compound CN(CC(Nc(cc1)cc(C(F)(F)F)c1Cl)=O)C(CC1)(CCN1C1CCCC1)c(cc1)ccc1-c1cc(C#N)ccc1 GEIBEOSSYAMBAM-UHFFFAOYSA-N 0.000 description 1
- MSJFHHISKJEGQB-UHFFFAOYSA-N CN(CC(Nc(cc1)cc(C(F)(F)F)c1F)=O)C(CC1)(CCN1C1CCCC1)c(cc1)ccc1-c1cc(C#N)ccc1 Chemical compound CN(CC(Nc(cc1)cc(C(F)(F)F)c1F)=O)C(CC1)(CCN1C1CCCC1)c(cc1)ccc1-c1cc(C#N)ccc1 MSJFHHISKJEGQB-UHFFFAOYSA-N 0.000 description 1
- MGCFHSVBCSGRPN-UHFFFAOYSA-N CN(CC(Nc(cc1)cc(Cl)c1F)=O)C(CC1)(CCN1C1CCCC1)c(cc1)ccc1-c1cc(C#N)ccc1 Chemical compound CN(CC(Nc(cc1)cc(Cl)c1F)=O)C(CC1)(CCN1C1CCCC1)c(cc1)ccc1-c1cc(C#N)ccc1 MGCFHSVBCSGRPN-UHFFFAOYSA-N 0.000 description 1
- WBHGNBSQTQEBFM-UHFFFAOYSA-N CN(CC(Nc1cc(Cl)cc(Cl)c1)=O)C(CC1)(CCN1C1CCCC1)c(cc1)ccc1-c1cc(C#N)ccc1 Chemical compound CN(CC(Nc1cc(Cl)cc(Cl)c1)=O)C(CC1)(CCN1C1CCCC1)c(cc1)ccc1-c1cc(C#N)ccc1 WBHGNBSQTQEBFM-UHFFFAOYSA-N 0.000 description 1
- KULCUMUGLWUBMF-UHFFFAOYSA-N CN(CC(Nc1cc(F)cc(F)c1)=O)C(CC1)(CCN1C1CCCC1)c(cc1)ccc1-c1cc(C#N)ccc1 Chemical compound CN(CC(Nc1cc(F)cc(F)c1)=O)C(CC1)(CCN1C1CCCC1)c(cc1)ccc1-c1cc(C#N)ccc1 KULCUMUGLWUBMF-UHFFFAOYSA-N 0.000 description 1
- YLGSTSPEVYIYJK-UHFFFAOYSA-N CN(CC1)CCC1(c(cc1)ccc1-c1cccc(C#N)c1)OCC(NC1=CCCC=C1)=O Chemical compound CN(CC1)CCC1(c(cc1)ccc1-c1cccc(C#N)c1)OCC(NC1=CCCC=C1)=O YLGSTSPEVYIYJK-UHFFFAOYSA-N 0.000 description 1
- GHZIOVUPCYHGQH-UHFFFAOYSA-N N#Cc1cc(-c2ccc(C(CC3)(CCN3C3CCCC3)N(CC3CC3)CC(Nc(cc3C(F)(F)F)ccc3Cl)=O)cc2)ccc1 Chemical compound N#Cc1cc(-c2ccc(C(CC3)(CCN3C3CCCC3)N(CC3CC3)CC(Nc(cc3C(F)(F)F)ccc3Cl)=O)cc2)ccc1 GHZIOVUPCYHGQH-UHFFFAOYSA-N 0.000 description 1
- WBKWYXGKFKATLZ-UHFFFAOYSA-N N#Cc1cc(-c2ccc(C3(CCC(Nc(cc4F)ccc4F)=O)CCNCC3)cc2)ccc1 Chemical compound N#Cc1cc(-c2ccc(C3(CCC(Nc(cc4F)ccc4F)=O)CCNCC3)cc2)ccc1 WBKWYXGKFKATLZ-UHFFFAOYSA-N 0.000 description 1
- YNJSYEINACIJPY-UHFFFAOYSA-N N#Cc1cccc(-c2ccc(C(CC3)(CCN3C3CCCC3)N(CC3CC3)CC(Nc3cc(F)cc(F)c3)=O)cc2)c1 Chemical compound N#Cc1cccc(-c2ccc(C(CC3)(CCN3C3CCCC3)N(CC3CC3)CC(Nc3cc(F)cc(F)c3)=O)cc2)c1 YNJSYEINACIJPY-UHFFFAOYSA-N 0.000 description 1
- CMJMDFJQANEZRN-UHFFFAOYSA-N N#Cc1cccc(-c2ccc(C(CC3)(CCN3C3CCCC3)NCC(Nc(cc3)cc(C(F)(F)F)c3Cl)=O)cc2)c1 Chemical compound N#Cc1cccc(-c2ccc(C(CC3)(CCN3C3CCCC3)NCC(Nc(cc3)cc(C(F)(F)F)c3Cl)=O)cc2)c1 CMJMDFJQANEZRN-UHFFFAOYSA-N 0.000 description 1
- LYRXVDROYYSQFE-UHFFFAOYSA-N N#Cc1cccc(-c2ccc(C(CC3)(CCN3C3CCCC3)NCC(Nc(cc3)cc(C(F)(F)F)c3F)=O)cc2)c1 Chemical compound N#Cc1cccc(-c2ccc(C(CC3)(CCN3C3CCCC3)NCC(Nc(cc3)cc(C(F)(F)F)c3F)=O)cc2)c1 LYRXVDROYYSQFE-UHFFFAOYSA-N 0.000 description 1
- LQJDHAFALWAPFW-UHFFFAOYSA-N N#Cc1cccc(-c2ccc(C(CC3)(CCN3C3CCCC3)NCC(Nc(cc3)cc(Cl)c3F)=O)cc2)c1 Chemical compound N#Cc1cccc(-c2ccc(C(CC3)(CCN3C3CCCC3)NCC(Nc(cc3)cc(Cl)c3F)=O)cc2)c1 LQJDHAFALWAPFW-UHFFFAOYSA-N 0.000 description 1
- SVHPMIZTMLNADU-UHFFFAOYSA-N N#Cc1cccc(-c2ccc(C(CC3)(CCN3C3CCCC3)NCC(Nc3cc(Cl)cc(Cl)c3)=O)cc2)c1 Chemical compound N#Cc1cccc(-c2ccc(C(CC3)(CCN3C3CCCC3)NCC(Nc3cc(Cl)cc(Cl)c3)=O)cc2)c1 SVHPMIZTMLNADU-UHFFFAOYSA-N 0.000 description 1
- ZLWGIZOKJOVYDM-UHFFFAOYSA-N N#Cc1cccc(-c2ccc(C(CC3)(CCN3C3CCCC3)NCC(Nc3cc(F)cc(F)c3)=O)cc2)c1 Chemical compound N#Cc1cccc(-c2ccc(C(CC3)(CCN3C3CCCC3)NCC(Nc3cc(F)cc(F)c3)=O)cc2)c1 ZLWGIZOKJOVYDM-UHFFFAOYSA-N 0.000 description 1
- BKRQDIBQZSATRM-UHFFFAOYSA-N N#Cc1cccc(-c2ccc(C(CC3)(CCN3C3CCCC3)NCC(Nc3ccccc3)=O)cc2)c1 Chemical compound N#Cc1cccc(-c2ccc(C(CC3)(CCN3C3CCCC3)NCC(Nc3ccccc3)=O)cc2)c1 BKRQDIBQZSATRM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33336701P | 2001-11-26 | 2001-11-26 | |
| PCT/US2002/037956 WO2003045918A1 (en) | 2001-11-26 | 2002-11-25 | Piperidine-based mch antagonists for treatment of obesity and cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009187565A Division JP2009256390A (ja) | 2001-11-26 | 2009-08-12 | 肥満およびｃｎｓ障害の処置のためのピペリジン系ｍｃｈアンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005510563A JP2005510563A (ja) | 2005-04-21 |
| JP2005510563A5 true JP2005510563A5 (enExample) | 2006-01-12 |
Family
ID=23302485
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003547370A Pending JP2005510563A (ja) | 2001-11-26 | 2002-11-25 | 肥満およびｃｎｓ障害の処置のためのピペリジン系ｍｃｈアンタゴニスト |
| JP2009187565A Pending JP2009256390A (ja) | 2001-11-26 | 2009-08-12 | 肥満およびｃｎｓ障害の処置のためのピペリジン系ｍｃｈアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009187565A Pending JP2009256390A (ja) | 2001-11-26 | 2009-08-12 | 肥満およびｃｎｓ障害の処置のためのピペリジン系ｍｃｈアンタゴニスト |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6664273B2 (enExample) |
| EP (1) | EP1448526B1 (enExample) |
| JP (2) | JP2005510563A (enExample) |
| KR (1) | KR20040058307A (enExample) |
| CN (1) | CN1592739A (enExample) |
| AR (1) | AR037429A1 (enExample) |
| AT (1) | ATE446286T1 (enExample) |
| AU (1) | AU2002350269B2 (enExample) |
| CA (1) | CA2467857C (enExample) |
| DE (1) | DE60234116D1 (enExample) |
| ES (1) | ES2333415T3 (enExample) |
| HU (1) | HUP0402404A3 (enExample) |
| IL (1) | IL161717A0 (enExample) |
| MX (1) | MXPA04004956A (enExample) |
| PE (1) | PE20030809A1 (enExample) |
| TW (1) | TW200301115A (enExample) |
| WO (1) | WO2003045918A1 (enExample) |
| ZA (1) | ZA200403784B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070135425A1 (en) * | 2001-05-04 | 2007-06-14 | Amgen Inc. | Fused heterocyclic compounds |
| US6809104B2 (en) * | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
| BR0209932A (pt) * | 2001-05-22 | 2004-10-13 | Neurogen Corp | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, preparação farmacêutica embalada, métodos para modular ligação de mch a um receptor de mch e de mvc, para alterar a atividade de transdução de sinal de um receptor de mch em uma célula, para tratar uma doença ou distúrbio associado com a ativação de receptor de mch patogênico obesidade e para determinar a presença ou ausência de receptor de mch em uma amostra, e, uso de um composto |
| AU2002352878B2 (en) | 2001-11-27 | 2007-11-22 | Merck Sharp & Dohme Corp. | 2-Aminoquinoline compounds |
| WO2003060475A2 (en) * | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues |
| MXPA05004739A (es) * | 2002-11-06 | 2005-08-02 | Tularik Inc | Compuestos heterociclicos fusionados. |
| AU2003284402A1 (en) * | 2002-11-15 | 2004-06-15 | Yamanouchi Pharmaceutical Co., Ltd. | Antagonist to melanin-concentrating hormone receptor |
| AU2004209505B2 (en) * | 2003-02-10 | 2009-07-23 | Banyu Pharmaceutical Co., Ltd. | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient |
| US20040242568A1 (en) | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| GB0310724D0 (en) * | 2003-05-09 | 2003-06-11 | Glaxo Group Ltd | Chemical compounds |
| WO2005005419A1 (en) * | 2003-06-30 | 2005-01-20 | Schering Corporation | Mch antagonists for the treatment of obesity |
| MXPA06001601A (es) | 2003-08-13 | 2006-08-25 | Takeda Pharmaceutical | Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa. |
| AR045496A1 (es) * | 2003-08-29 | 2005-11-02 | Schering Corp | Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados |
| WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| EP1667958A2 (en) | 2003-10-01 | 2006-06-14 | The Procter & Gamble Company | Melanin concentrating hormone antagonists |
| CN102079743B (zh) * | 2004-03-15 | 2020-08-25 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| EP1729772B8 (en) * | 2004-03-24 | 2017-04-19 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine glycine transporter inhibitors |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| ES2327763T3 (es) * | 2004-07-16 | 2009-11-03 | Schering Corporation | Heterociclilos utilizados como antagonistas del receptor de la hormona concentrada de melanina para el tratamiento de la obesidad y trastornos relacionados. |
| TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| JP2008521821A (ja) * | 2004-11-29 | 2008-06-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
| JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| AU2005317846B2 (en) * | 2004-12-21 | 2011-12-08 | Merck Sharp & Dohme Limited | Piperidine and azetidine derivatives as GlyT1 inhibitors |
| US7786308B2 (en) * | 2005-03-28 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Muscarinic modulators |
| NZ566799A (en) | 2005-09-14 | 2011-04-29 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
| WO2007035629A2 (en) | 2005-09-16 | 2007-03-29 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
| WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| TW200812963A (en) | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| WO2007118853A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| PL2073810T3 (pl) * | 2006-09-13 | 2012-01-31 | Takeda Pharmaceuticals Co | Zastosowanie 2-6-(3-amino-piperydyn-1-ylo)-3-metylo-2,4-diokso-3,4-dihydro-2H-pirymidyn-1-ylometylo-4-fluoro-benzonitrylu do leczenia cukrzycy, raka, zaburzeń autoimmunizacyjnych i zakażeń HIV |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| WO2008124118A1 (en) * | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| WO2008128126A1 (en) | 2007-04-11 | 2008-10-23 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| WO2009040659A2 (en) | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| US20170280749A1 (en) * | 2011-06-09 | 2017-10-05 | Requis Pharmaceuticals | Antihistamines Combined with Dietary Supplements for Improved Health |
| JP6883817B2 (ja) * | 2017-02-10 | 2021-06-09 | 株式会社Ｉｈｉエアロスペース | ロケットモータ |
| KR200487142Y1 (ko) | 2017-05-31 | 2018-08-10 | 주식회사 에이치에스씨 | 2차코일이 일체로 형성된 트랜스포머용 가이더 |
| KR102695210B1 (ko) | 2018-06-05 | 2024-08-13 | 크리네틱스 파마슈티칼스, 인크. | 멜라노코르틴 아형-2 수용체(mc2r) 길항제 및 이의 용도 |
| WO2021091788A1 (en) | 2019-11-07 | 2021-05-14 | Crinetics Pharmaceuticals, Inc. | Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof |
| JP7672406B2 (ja) * | 2019-12-18 | 2025-05-07 | クリネティックス ファーマシューティカルズ，インク． | Ｇｅｍ－二置換ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用 |
| JP7651574B2 (ja) | 2019-12-23 | 2025-03-26 | クリネティックス ファーマシューティカルズ，インク． | スピロ環式ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用 |
| BR112023018816A2 (pt) | 2021-03-19 | 2023-10-31 | Crinetics Pharmaceuticals Inc | Antagonista do receptor de melanocortina subtipo-2 (mc2r) para o tratamento de doença |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL267843A (enExample) * | 1960-08-03 | |||
| DE4107857A1 (de) | 1991-03-12 | 1992-09-17 | Thomae Gmbh Dr K | Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US5908830A (en) | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
| US6043246A (en) | 1996-12-03 | 2000-03-28 | Banyu Pharmaceutical Co., Ltd. | Urea derivatives |
| US5953440A (en) | 1997-12-02 | 1999-09-14 | Sensar, Inc. | Method of measuring the focus of close-up images of eyes |
| ATE232200T1 (de) | 1998-06-08 | 2003-02-15 | Schering Corp | Neuropeptid y5-rezeptorantagonisten |
| US7115750B1 (en) * | 1999-09-20 | 2006-10-03 | Takeda Pharmaceutical Company Limited | Melanin concentrating hormone antagonist |
| PT1285651E (pt) | 2000-04-28 | 2010-10-21 | Takeda Pharmaceutical | Antagonistas da hormona concentradora da melanina |
| EP1283199A4 (en) | 2000-05-16 | 2003-12-17 | Takeda Chemical Industries Ltd | MELANINE CONCENTRATING HORMONE ANTAGONISTS |
| CA2443672C (en) | 2001-04-12 | 2011-03-29 | Pharmacopeia, Inc. | Aryl and biaryl piperidines used as mch antagonists |
| GB0124627D0 (en) | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
-
2002
- 2002-11-25 US US10/303,205 patent/US6664273B2/en not_active Expired - Fee Related
- 2002-11-25 IL IL16171702A patent/IL161717A0/xx unknown
- 2002-11-25 CN CNA028235118A patent/CN1592739A/zh active Pending
- 2002-11-25 KR KR10-2004-7007712A patent/KR20040058307A/ko not_active Withdrawn
- 2002-11-25 AT AT02786803T patent/ATE446286T1/de not_active IP Right Cessation
- 2002-11-25 HU HU0402404A patent/HUP0402404A3/hu unknown
- 2002-11-25 JP JP2003547370A patent/JP2005510563A/ja active Pending
- 2002-11-25 ES ES02786803T patent/ES2333415T3/es not_active Expired - Lifetime
- 2002-11-25 WO PCT/US2002/037956 patent/WO2003045918A1/en not_active Ceased
- 2002-11-25 AU AU2002350269A patent/AU2002350269B2/en not_active Ceased
- 2002-11-25 CA CA2467857A patent/CA2467857C/en not_active Expired - Fee Related
- 2002-11-25 MX MXPA04004956A patent/MXPA04004956A/es active IP Right Grant
- 2002-11-25 AR ARP020104529A patent/AR037429A1/es unknown
- 2002-11-25 EP EP02786803A patent/EP1448526B1/en not_active Expired - Lifetime
- 2002-11-25 DE DE60234116T patent/DE60234116D1/de not_active Expired - Lifetime
- 2002-11-26 TW TW091134320A patent/TW200301115A/zh unknown
- 2002-11-26 PE PE2002001134A patent/PE20030809A1/es not_active Application Discontinuation
-
2004
- 2004-05-17 ZA ZA200403784A patent/ZA200403784B/en unknown
-
2009
- 2009-08-12 JP JP2009187565A patent/JP2009256390A/ja active Pending